28 June 2021 - Valoctocogene roxaparvovec MAA granted request for accelerated assessment.
BioMarin Pharmaceutical announced today that the company resubmitted a marketing authorisation application to the EMA for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe haemophilia A.